Company: GIFLF
Filing Date: 2025-05-12
Form Type: 6-K
Source: 0001104659-25-047168
Chunk: 3

Company: Grifols SA
Filing Date: 2025-05-12
Form: 6-K
Chunk 3
---
4.5x and EUR 8,149 million, respectively, with a strong liquidity
position of EUR 1,675 million. Unlike prior years where Q1 typically led to a releveraging, in Q1’25 leverage improved versus FY’24
- underscoring the strength and normalisation of Grifols´ business performance.

Nacho Abia, Chief Executive
Officer, commented: “Building on our record-setting performances in 2023 and 2024, our first quarter clearly demonstrates continued
momentum as we focus on executing our strategic plan. Healthy underlying demand in Biopharma and across all parts of our business, coupled
with strong operational execution, positions Grifols for consistent growth throughout 2025. While we continue to monitor evolving macroeconomic
and policy developments, the long-established Grifols strategy of being local in our largest markets, where we have established self-sufficient,
regional plasma ecosystems with vertically integrated operations, helps to better insulate us from broader marketplace challenges.”

Rahul Srinivasan, Chief Financial
Officer, said, “Amid a dynamic macroeconomic environment, our business continues to demonstrate strong momentum, reinforcing our
confidence in the full year outlook. We remain focused on disciplined execution – delivering for our patients and customers, capitalizing
on the secular growth across our core markets, and translating that strong growth into sustained improvement of free cash flow generation.”

Page 2 of 4

2025 Guidance

Grifols reaffirms its guidance for
2025 as disclosed at its Capital Markets Day on February 27, 20256.

Key Financials

Alternative Performance Measures (APMs)

This document contains the following
Alternative Performance Measures (APMs): Consolidated EBITDA Reported, Consolidated EBITDA Adjusted, Like-for-Like, Leverage Ratio as
per the Credit Facility, Net Debt as per the Credit Facility, Free Cash Flow, Working Capital, and non-recurring items. For further details
on the definition, explanation on the use, and reconciliation of APMs, please see the Appendix of the Presentation as well as the “Alternative
Performance Measures” document from Grifols website .

CONFERENCE CALL

Grifols will host a conference call
today, May 12, 2025, at 6:30pm CET/12:30pm EST to provide review of the company’s business results for the first quarter of 2025.
To view and listen to the webcast and view